VTE*
Apixaban Randomized
Controlled Clinical Trial Data
Controlled Clinical Trial Data
Agnelli G (N Engl J Med. 2013)
AMPLIFY weight and BMI subgroup analysis
AMPLIFY weight and BMI subgroup analysis
Cohen AT (Adv Ther. 2021)
AMPLIFY post hoc analysis Extremes of body weight and exposure
AMPLIFY post hoc analysis Extremes of body weight and exposure
Agnelli G (N Engl J Med. 2013)
AMPLIFY-EXT weight subgroup analysis
AMPLIFY-EXT weight subgroup analysis
Real-World Data
Cohen A (J Clin Med. 2021)
Effectiveness and safety of apixaban vs. warfarin
in VTE patients with obesity and morbid obesity.
Effectiveness and safety of apixaban vs. warfarin
in VTE patients with obesity and morbid obesity.
Perino AC (Circ Cardiovasc Qual Outcomes.
2021)
Anti coagulation and outcomes by weight/BMI in VTE from Veterans Health Administration.
2021)
Anti coagulation and outcomes by weight/BMI in VTE from Veterans Health Administration.
Crouch A (Pharmacotherapy. 2022)
Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin
for treatment of venous thromboembolism in
patients with severe obesity.
Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin
for treatment of venous thromboembolism in
patients with severe obesity.
Kushnir M (Lancet Haematol. 2019)
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
